NCT07917390
ALT-100 Monoclonal Antibody (mAb) in Bone-Predominant Metastatic Androgen Pathway Modulation Resistant (APMR) Prostate Cancer -- The ALTAR-100 Trial
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Incidence of dose limiting toxicities
Timeframe: first 30 days of treatment with ALT-100
Percentage of participants who achieve a PSA decrease of at least 30%
Timeframe: After up to 6 months of treatment with ALT-100
Percentage of participants who achieve a PSA decrease of at least 50%
Timeframe: After up to 6 months of treatment with ALT-100
Radiographic progression-free survival
Timeframe: After up to 6 months of treatment with ALT-100
Secondary (20)
Maximum plasma concentration of ALT-100
Time to reach maximum plasma concentration of ALT-100
Area under the curve (AUC) up to the last measurable plasma concentration for ALT-100
Area under the curve (AUC) over the dosing interval for ALT-100
Half-life for ALT-100
Show 15 moreShow less
Trough plasma concentration for ALT-100
Average plasma concentration during a dosing interval for ALT-100
Plasma concentration of eNAMPT
Plasma concentration of IL-6
Plasma concentration of IL-8
Plasma concentration of TNF-a
Plasma concentration of IL-1b
Plasma concentration of IL-1RA
Plasma concentration of Ang2
Plasma concentration of VEGF
Plasma concentration of BMP-2
Plasma concentration of PDGF-BB
Plasma concentration of osteopontin
Plasma concentration of osteocalcin
Plasma concentration of bALP
Arms and interventions
Phase 1 - Dose level 1 - 1.0 mg/kg ALT-100Experimental
This is the starting dose for the phase 1 portion of the study.
Phase 1 - Dose Level 2 - 4.0 mg/kg of ALT-100Experimental
This is the second dose level that will be tested in the phase 1 portion of the study.
Phase 2 - Recommended phase 2 dose of ALT-100Experimental
Participants randomized to this arm will receive the recommended phase 2 dose determined in the phase 1 portion of the study.
Phase 2 - Comparator dose of ALT-100Active comparator
Participants randomized to this arm will receive a comparator dose of ALT-100 that is not the recommended phase 2 dose determined in phase 1.
Biologicals: ALT-100